Immunological incompatibility as a basis for cancer curing and vaccination

Projektinformationen

ULISES

ID Finanzhilfevereinbarung: 899708

DOI 10.3030/899708

Projekt abgeschlossen

EK-Unterschriftsdatum 18 Juni 2020

Startdatum 1 Oktober 2020

Enddatum 30 Juni 2024

Finanziert unter

• EXCELLENT SCIENCE - Future and Emerging Technologies (FET)

Gesamtkosten € 2 977 160,00

EU-Beitrag € 2 977 160,00

Koordiniert durch

FUNDACIO DE RECERCA CLINIC BARCELONA-INSTITUT D INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER
Spain

Leistungen

Websites, patent fillings, videos etc. (2)

Web site social media and logo

Launch of the project visual identity logo and other grapic elements the project website and social media channels Twitter account and LinkedIn page

Communication materials

Communication materials will include the project flyer a short presentation video an official power point presentation of the project a rollup poster

Documents, reports (5)

First set of potentially useful monoclonal anti-HLA-A antibodies

Description of a first set of potentially useful monoclonal antiHLAA antibodies capable of reacting against the alloHLA antigens expressed on the surface of tumour cells

Synthesis and characterization of NPs

NPs will be prepared following solgel routes and fully characterized using different techniques including electron microscopy powder xray diffraction porosimetry etc

Report on establishment of optimal collection, processing, storing and analysis of biological materials from patients

A report explaining the establishment of optimal collection processing storing and analysis of biological materials from pancreatic cancer patients

Production of transfection grade plasmid DNA (pDNA) to be used in T3.4 (assessment of pDNA effect in target cells)

Required amounts of pDNA will be produced following standard internal procedures

Constitution of the different management committees

The following committees will be formally constituted1 Project Management and Steering Committee PMSC 2 Scientific and Technical Committee STC3 Innovation and Exploitation Committee IXC4 Ethics Management Committee EMC

Open Research Data Pilot (1)

Data Management Plan

The Data Management Plan will provide the protocols to be followed in the management and treatment of data

Veröffentlichungen

Peer reviewed articles (1)

A Comprehensive Transcriptional Signature in Pancreatic Ductal Adenocarcinoma Reveals New Insights into the Immune and Desmoplastic Microenvironments

Autoren: Irene Pérez-Díez, Zoraida Andreu Marta R Hidalgo, Carla Perpiñá-Clérigues, Lucía Fantín, Antonio Fernandez-Serra, María de la Iglesia-Vaya, José A Lopez-Guerrero, Francisco García-García
Veröffentlicht in: Cancers (Basel), Ausgabe 2023 May 24;15(11):2887, 2023, ISSN 2072-6694
Herausgeber: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/cancers15112887